

Special Issue

Vaccines for Zoonotic, High-Consequence Pathogens: A One Health Approach to Disease Control

Message from the Guest Editors

Our growing population has resulted in increased wildlife interactions through habitat encroachment by agriculture, mining, and housing development. In addition, continued hunting of wild animals as food sources and an increased demand for exotic pets have facilitated opportunities for pathogens to infect new species, including humans. Global movement of humans and goods has allowed the spread of novel viruses around the world at an increasingly rapid pace, making disease control efforts exceptionally challenging. The introductions of influenza (of swine or avian origin), Nipah virus, Hendra virus, Ebola virus, and novel corona viruses (SARS, MERS, and now SARS-2) into the human population highlight the need for disease control measures directed at both human and animal hosts. This Special Issue will focus on the One Health approach to vaccine development to control infectious disease in both animal and human populations. All types of articles will be considered for publication, including short reports, primary research articles, and reviews.

Guest Editors

Dr. Richard Bennett

Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA

Dr. Jessica Spengler

National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USA

Deadline for manuscript submissions

closed (31 March 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/49241

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).